AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson’s Disease

Shots: The P-III M15-736 Study evaluates the efficacy, safety & tolerability of ABBV-951 to levodopa/carbidopa in 130 adult patients with advanced PD across 80 sites globally The study met its 1EPs of increase from baseline in “On” time (hours) without troublesome dyskinesia after 12wks. based on PD Diary. The therapy also showed an improvement from …

AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson’s Disease Read More »